Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Robert Smythe

Internal Medicine Yuma, AZ Medical Doctor

NPI 1306874607 CMS profile 104243

2775 S 8Th Ave, Yuma, AZ 85364

Open in the dashboard

General payments

$4,604

254 records reported · program years 2019–2025

Research payments

$440

Paid to them · 1 record reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$1,071,656 paid to institutions, not to them · program years 2022–2025

Through program year 2025, Robert Smythe of Yuma, AZ is reported in the CMS Open Payments database as having received $4,604 across 254 general payments and $440 in research payments paid to them. Separately, studies naming them as principal investigator received $1,071,656 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 89th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $522 32
2024 General $574 34
2023 General $733 42
2023 Research $440 1
2022 General $721 38
2021 General $1,208 51
2020 General $416 28
2019 General $430 29

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Robert Smythe
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Robert Smythe were reported at $522. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Robert Smythe Internal Medicine median Middle half National median
2019 $430 $159 $48–$570 $163
2020 $416 $119 $33–$402 $114
2021 $1,208 $135 $37–$521 $132
2022 $721 $141 $42–$496 $149
2023 $733 $149 $45–$519 $160
2024 $574 $154 $47–$537 $164
2025 $522 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $1,026 88 payments
  2. Mayne Pharma Inc. $412 1 payment
  3. Lilly USA, LLC $293 17 payments
  4. Novo Nordisk Inc $289 12 payments
  5. Allergan Inc. $265 16 payments
  6. Bayer HealthCare Pharmaceuticals Inc. $258 10 payments
  7. Pfizer Inc. $206 12 payments
  8. Teva Pharmaceuticals USA, Inc. $191 11 payments
  9. Amgen Inc. $185 11 payments
  10. Corcept Therapeutics $165 5 payments
  11. Other $1,314 71 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $4,604 254 payments
Products named General payments · program years 2019–2025
  1. UBRELVY $769 61 payments
  2. QULIPTA $378 38 payments
  3. Kerendia $258 10 payments
  4. RYBELSUS $227 8 payments
  5. MOUNJARO $188 10 payments
  6. Korlym $165 5 payments
  7. Ozempic $144 10 payments
  8. BOTOX $140 6 payments
  9. INJECTAFER $138 6 payments
  10. VRAYLAR $112 10 payments
  11. Other $2,693 158 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Eli Lilly and Company $440 1 payment

Prescribing to Medicare patients

Part D · data year 2024 · 65 drugs

Part D claims

2,160

Median for Internal Medicine: 777

Drug cost

$189,949

Median for Internal Medicine: $73,373

Branded share of claims

15.9%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 43 $58,113
Ozempic Semaglutide Brand 25 $44,982
Jardiance Empagliflozin Brand 29 $37,381
Mounjaro Tirzepatide Brand 14 $14,632
Rosuvastatin Calcium Generic 176 $2,926
Losartan Potassium Generic 155 $1,815
Celecoxib Generic 12 $1,762
Naproxen Generic 35 $1,595
Tamsulosin Hcl Generic 57 $1,576
Progesterone Progesterone, Micronized Brand 18 $1,285

The 10 drugs with the highest cost, of 65 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 105 billing codes

Paid by Medicare

$783,424

Of which drugs: $87,184

Medicare patients

1,922

Average age 76

Services billed

45,982

1,162 women, 760 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 44%
Diabetes 27%
Ischemic heart disease 23%
Chronic kidney disease 22%
Atrial fibrillation 16%
Depression 15%
Osteoporosis 15%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Pcv20 vaccine im 90677 Office 179 182 $52,883
Vaccine for influenza for injection into muscle 90662 Office 418 418 $24,558
Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg J0702 Office 212 1,004 $4,638
Vaccine for influenza for administration into muscle, 0.5 ml dosage 90656 Office 67 67 $1,445
Vaccine for influenza for administration into muscle, 0.5 ml dosage 90674 Office 23 23 $770
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 98 476 $320
Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg J3420 Office 33 82 $68
Injection, ketorolac tromethamine, per 15 mg J1885 Office 24 108 $51

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 16 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
UBRELVY
  • AbbVie, Inc. $81
$81 — —
QULIPTA
  • AbbVie, Inc. $62
$62 — —
MOUNJARO
  • Lilly USA, LLC $33
$33 14 —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $28
$28 — —
Veozah
  • Astellas Pharma US Inc $20
$20 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 16 in the dashboard with a free account

Records

255 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record